Evidence map›Paper›PMID 41199910›Full record

ArticleCase reports in hematology2025

Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-Type

Shuting Chang, Zhijuan Pan, Yiqun Zhang, Ying Zhang, Jiajia Sun, Yanru Guo, Xinlei Guo, Zhiping Guo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuting ChangDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.ORCID https://orcid.org/0009-0007-5673-1733
Zhijuan PanDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.
Yiqun ZhangDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.
Ying ZhangDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.
Jiajia SunDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.
Yanru GuoDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.
Xinlei GuoDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.ORCID https://orcid.org/0009-0009-1773-483X
Zhiping GuoDepartment of Hematology, Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital), The Ninth Clinical Medical College of Shanxi Medical University, Taiyuan 030006, China.ORCID https://orcid.org/0000-0003-3908-3811

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many tyrosine kinase inhibitors show nonspecific activity against multiple kinases, causing off-target effects when used in a broad patient population. This study evaluated the effectiveness of gilteritinib combined with venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) with wild-type

Indexed as

acute myeloid leukemiagilteritinibmyelodysplastic neoplasmsrefractoryrelapsedvenetoclaxwild-type FLT3

Identifiers

PMID41199910
PMCPMC12588749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.